Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells (Q43059181)

13 November 2017

title

Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells (English)

1 reference

13 November 2017

0 references

1 reference

1 reference

2

A Tefferi

1 reference

13 November 2017

T Lasho

1

1 reference

13 November 2017

A Pardanani

series ordinal

3

1 reference

13 November 2017

publication date

20 May 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

24

1 reference

13 November 2017

issue

7

1 reference

13 November 2017

page(s)

1378-1380

1 reference

Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.109

21 January 2018

Identifiers

DOI

10.1038/LEU.2010.109

1 reference

Dimensions Publication ID

13 November 2017

1002211565

0 references

1 reference